Comparative Pharmacology
Head-to-head clinical analysis: BUTOCONAZOLE NITRATE versus SPECTAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTOCONAZOLE NITRATE versus SPECTAZOLE.
BUTOCONAZOLE NITRATE vs SPECTAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Econazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing cell membrane permeability.
Intravaginal administration: 100 mg (one applicatorful of 2% cream) once daily for 3 days; or 100 mg (one suppository) once daily for 3 days; or 5 g (one applicatorful of 4% cream) as a single dose.
Apply a thin layer to affected area once daily for 4-4 weeks; duration depends on indication.
None Documented
None Documented
Terminal half-life is approximately 21–24 hours, supporting once-daily or twice-weekly dosing for vaginal candidiasis.
Terminal elimination half-life is approximately 24-30 hours in patients with normal renal function, allowing once-daily dosing.
Primarily hepatic metabolism with <5% excreted unchanged in urine; fecal elimination accounts for ~30% of metabolites.
Primarily renal: approximately 70% of an oral dose is excreted unchanged in urine; biliary/fecal excretion accounts for ~20%, with the remainder as metabolites.
Category A/B
Category C
Antifungal
Antifungal